TOP TEN perturbations for 38924_s_at (Homo sapiens)
Organism: Homo sapiens
Gene: 38924_s_at
Selected probe(set): 209027_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38924_s_at (209027_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
kidney transplantation study 15 (8 week) / normal monocyte (CD14+) sample
Relative Expression (log2-ratio):-3.4424982Number of Samples:2 / 5
| Experimental | kidney transplantation study 15 (8 week) |
| CD14+ monocyte samples derived from kidney transplant patients 8 weeks post-transplantation. Samples were collected 8 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH). | |
| Control | normal monocyte (CD14+) sample |
| CD14+ monocyte samples derived from healthy control subjects. |
esophagus cancer study 1 (PDX; squamous cell carcinoma, NOS; metastatic) / esophagus cancer study 1 (PDX; squamous cell carcinoma, NOS; primary)
Relative Expression (log2-ratio):-3.081252Number of Samples:2 / 3
| Experimental | esophagus cancer study 1 (PDX; squamous cell carcinoma, NOS; metastatic) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary squamous cell carcinoma, NOS of the oesophagus (subcutaneously implanted). Metastatic site of patient tumor sample is not reported. | |
| Control | esophagus cancer study 1 (PDX; squamous cell carcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary squamous cell carcinoma, NOS of the oesophagus (subcutaneously implanted). |
myotonic dystrophy study 4 (skeletal muscle; DM1) / normal skeletal muscle tisuue (fetal)
Relative Expression (log2-ratio):-2.596922Number of Samples:5 / 3
| Experimental | myotonic dystrophy study 4 (skeletal muscle; DM1) |
| Unspecified skeletal muscle biopsies obtained from patients with myotonic dystrophy type 1 (DM1). | |
| Control | normal skeletal muscle tisuue (fetal) |
| Commercially purchased normal fetal skeletal muscle tissue samples. |
brefeldin A study 1 (0.5ug/ml; HCT 116) / untreated HCT 116 cell sample
Relative Expression (log2-ratio):2.3967848Number of Samples:3 / 3
| Experimental | brefeldin A study 1 (0.5ug/ml; HCT 116) |
| Human colon carcinoma cell line HCT116 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
| Control | untreated HCT 116 cell sample |
| Human colon carcinoma cell line HCT116 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
uterine/pelvic pathology study 2 (pro. MCP) / uterine/pelvic pathology study 2 (late se MCP)
Relative Expression (log2-ratio):-2.3145628Number of Samples:15 / 2
| Experimental | uterine/pelvic pathology study 2 (pro. MCP) |
| Endometrial tissue samples collected from women with uterine/pelvic pathology in the proliferative menstrual cycle phase (MCP). The group contained cycling women 20 – 50 years old with symptomatic uterine fibroids, pelvic organ prolapse, and adenomyosis. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded. | |
| Control | uterine/pelvic pathology study 2 (late se MCP) |
| Endometrial tissue samples collected from women with uterine/pelvic pathology in the late secretory menstrual cycle phase (MCP). The group contained cycling women 20 – 50 years old with symptomatic uterine fibroids, pelvic organ prolapse, and adenomyosis. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded. |
Merkel cell carcinoma study 3 (metastatic) / normal skin tissue
Relative Expression (log2-ratio):-2.1117811Number of Samples:11 / 64
| Experimental | Merkel cell carcinoma study 3 (metastatic) |
| Metastatic tumor tissue from different metastatic sites (skin, lymph node, parotid gland) of patients with Merkel cell carcinoma of the skin. | |
| Control | normal skin tissue |
| Normal skin samples from healthy donors. |
endometriosis study 6 (minimal/mild endo.; pro. MCP) / normal endometrium tissue (pro. MCP)
Relative Expression (log2-ratio):-2.094491Number of Samples:12 / 20
| Experimental | endometriosis study 6 (minimal/mild endo.; pro. MCP) |
| Endometrial tissue samples from women with minimal or mild endometriosis and pelvic pain and/or infertility collected in the proliferative menstrual cycle phase (MCP). Endometriosis was diagnosed based on the revised American Fertility Society classification system. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded. | |
| Control | normal endometrium tissue (pro. MCP) |
| Normal endometrial tissue samples from women collected in the proliferative menstrual cycle phase (MCP). The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. |
lung cancer study 1 (PDX; large cell carcinoma, NOS; primary) / lung cancer study 1 (PDX; basaloid carcinoma; primary)
Relative Expression (log2-ratio):-2.0574207Number of Samples:4 / 3
| Experimental | lung cancer study 1 (PDX; large cell carcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary large cell carcinoma, NOS of the lung (subcutaneously implanted). | |
| Control | lung cancer study 1 (PDX; basaloid carcinoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary basaloid carcinoma of the lung (subcutaneously implanted). |
tunicamycin study 2 (2ug/ml; HCT 116) / untreated HCT 116 cell sample
Relative Expression (log2-ratio):2.04171Number of Samples:3 / 3
| Experimental | tunicamycin study 2 (2ug/ml; HCT 116) |
| Human colon carcinoma cell line HCT116 was treated with 2 ug/ml tunicamycin for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
| Control | untreated HCT 116 cell sample |
| Human colon carcinoma cell line HCT116 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
esophageal adenocarcinoma study 1 / normal esophageal epithelium sample
Relative Expression (log2-ratio):-2.00097Number of Samples:20 / 18
| Experimental | esophageal adenocarcinoma study 1 |
| Esophageal adenocarcinoma (EAC) samples of affected epithelium recovered by laser capture microdissection technique. | |
| Control | normal esophageal epithelium sample |
| Histologically normal esophageal squamous cell epithelium biopsy samples from patients that were investigated for esophageal pain, but diagnosed as healthy. |